Abstract The anti-arrhythmic efficacy of the late sodium channel current (late I Na ) inhibition has been convincingly demonstrated in the ventricles, particularly under conditions of prolonged ventricular repolarization. The value of late I Na block in the setting of atrial fibrillation (AF) remains poorly investigated. All sodium channel blockers inhibit both peak and late I Na and are generally more potent in inhibiting late vs. early I Na . Selective late I Na block does not prolong the effective refractory period (ERP), a feature common to practically all anti-AF agents. Although the late I Na blocker ranolazine has been shown to be effective in suppression of AF, it is noteworthy that at concentrations at which it blocks late I Na in the ventricles, it also potently blocks peak I Na in the atria, thus causing rate-dependent prolongation of ERP due to development of post-repolarization refractoriness. Late I Na inhibition in atria is thought to suppress intracellular calcium (Ca i )-mediated triggered activity, secondary to a reduction in intracellular sodium (Na i ). However, agents that block late I Na (ranolazine, amiodarone, vernakalant, etc) are also potent atrial-selective peak I Na blockers, so that the reduction of Na i loading in atrial cells by these agents can be in large part due to the block of peak I Na . The impact of late I Na inhibition is reduced by the abbreviation of the action potential that occurs in AF patients secondary to electrical remodeling. It stands to reason that selective late I Na block may contribute more to inhibition of Ca i -mediated triggered activity responsible for initiation of AF in clinical pathologies associated with a prolonged atrial APD (such as long QT syndrome). Additional studies are clearly needed to test this hypothesis.
Introduction
Specific inhibition of late sodium channel current (late I Na ) can effectively suppress ventricular arrhythmias, particularly under conditions of prolonged ventricular repolarization (such as long QT syndrome and heart failure) [1] [2] [3] [4] [5] . These anti-arrhythmic actions of selective late I Na inhibition are largely due to a reduction of intracellular calcium (Ca i ) loading, secondary to a decrease of intracellular sodium (Na i ). Augmented late I Na may significantly contribute to Na i loading, which brings calcium into the cell via reverse mode of sodium-calcium exchange. The electrophysiology and pharmacology of late I Na as well as the antiarrhythmic benefit of its inhibition have been studied mostly in ventricles. The value of block of late I Na for the suppression of atrial fibrillation (AF) remains poorly investigated. This review examines available data relative to the electrophysiology, pharmacology, and anti-AF ability of late I Na inhibition.
Electrophysiology of Late Sodium Current
Cardiac sodium channel current is comprised of two basic components: peak and late I Na . Peak I Na is responsible for phase 0 of the action potential, whereas late I Na contributes to the inward charge maintaining phase 2 and phase 3 ( Fig. 1) . Several mechanism are thought to contribute to the manifestation of late I Na , including 1) slow inactivation of the sodium channel [6] , 2) single as well as bursts of late reopening of the sodium channel [7] , and 3) a steady state current occurring within a window of voltage representing the overlap of steady state activation and inactivation of the sodium channel (window current [8] ).
Late I Na in Ventricular Cells
The amplitude of late I Na in the ventricles ranges from 0.1 to 1.0 % of that of peak I Na , depending on species, cell type, pathology, and conditions under which the currents are measured [2, 5] . However, due to a much longer duration during the action potential (100-300 for late I Na vs. 1-2 ms for peak I Na ), the total charge carried by late I Na can be considerable. Late I Na flows into the cell at potentials positive to −60 mV, peaking at −20 mV [9] . Prolongation of action potential duration (APD) increases and abbreviation of APD reduces the integral or total charge of late I Na .
The relative contribution of late I Na to Na i loading increases under pathophysiological conditions associated with an increase in late I Na density and prolongation of APD (such as heart failure) [2] . Myocardial ischemia in the ventricles is also associated with increased late I Na density [10] . In contrast, late I Na has been reported to be reduced in remodeled hypertrophied left ventricles (LV) in a canine chronic AV node block model [4] . It is also noteworthy that Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) can increase late I Na density [11] . There is significant regional heterogeneity in late and peak I Na density in canine ventricles. Left ventricular midmyocardial to subendocardial M cells have larger late and peak I Na densities compared to epicardial and endocardial myocytes [9] .
Late I Na in Atrial Cells
Late I Na is less studied in atrial vs. ventricular cells. The general characteristics of peak and late I Na appear to be similar in atrial and ventricular cells. However, there are atrioventricular electrophysiological differences that can modulate the relative contribution of late I Na to Na i loading. Because APD is shorter in atrium vs. ventricle (Fig. 2) , the atrial late I Na integral is likely to be smaller, as is its relative contribution to Na i loading. While the density of late I Na is similar in atrial and ventricular cells [12] , the density of peak I Na is significantly greater in atrial vs. ventricular myocytes [13, 14] . However, a more negative steady-state inactivation voltage in atrial vs. ventricular myocytes (~12 mV) [13, 14] as well as a more depolarized resting membrane potential (RMP) in atrial vs. ventricular myocytes reduce the availability of the sodium channel in atria vs. ventricles at the physiologically relevant RMP range. As a result, the range of available peak I Na appears to be similar in the two chambers as reflected by a similar range of maximum rate of rise of the action potential upstroke (V max , an index of peak I Na ) in the canine heart [15, 16] . The exception is Purkinje fiber action potentials, which display the largest peak I Na and V max in the heart. The value of V max generally positively correlates with conduction velocity, i.e., the larger the V max the faster conduction velocity and vice versa. There is a regional V max difference in healthy canine right atria (ranging from 356±60 V/s in the endocardial crista terminalis to 234±54 V/s in the epicardial appendage) [15] .
Because APD is commonly significantly abbreviated in remodeled atria (Fig. 2) , the integral of late I Na is likely to be smaller in remodeled vs. healthy atria. Properties of atrial late I Na in AF are poorly studied. The integral of late I Na (total charge) has been shown to be increased in atrial myocytes isolated from right atrial appendage of persistent AF vs. sinus rhythm patients (by 26 %) [17] . In this study, however, the late I Na integral in AF and non-AF patients was measured at the same pulse duration, not adjusted to the shorter APD observed in AF. It not known whether late I Na density is altered in patients with paroxysmal AF. The density of late I Na in left atria (but not in right atria) has been reported to be increased in a rabbit LV hypertrophy model (caused by hypertension) [18] . Available data relative to alterations of peak I Na in AF models and patients are Late I Na Control Late I Na Augmentation Reduction Fig. 1 Role of late I Na in the action potential (AP) of normal cardiomyocyte. The cardiac AP is comprised of 5 phases (denoted by the numbers). Phase 0, 1, 2, 3, and 4 represent depolarization, early repolarization, "plateau", late repolarization, and resting state, respectively. Peak I Na flows into the cell during phase 0 (upstroke of the AP; 1-2 ms duration) and late I Na during phase 2 and early phase 3 (at potentials positive to −60 mV, peaking at −20 mV; 100-300 ms duration). The density of peak I Na is significantly greater than that of late I Na . Action potential duration (APD) is measured at the level of 50-90 % of full repolarization (as depicted by the dashed lines). Specific augmentation of late I Na (an inward current) prolongs APD and block of this current abbreviates APD controversial. Peak I Na density in atrial myocytes has been reported to be reduced in persistent AF vs. SR patients in some studies [17] but not others [19] . A decrease in peak I Na activity was reported in remodeled canine [20] , but not goat atria [21] . Interestingly, Na i was shown to be reduced in canine atrial cells after 48 h of atrial-tachypacing [22] . The magnitude of late I Na is reverse-rate dependent, i.e., the faster the rate the less the magnitude of this current [9, [23] [24] [25] . The rate-dependent reduction of late I Na contributes to ratedependent APD abbreviation [9, 25] . The accelerationinduced reduction in late I Na is much greater than that of peak I Na (Fig. 3) . Thus, the relative contribution of late I Na in cardiac electrophysiology is thought to be more important when APD is longer and heart rate is slower.
Pharmacology of Late Sodium Current
All sodium channel blockers inhibit both peak and late I Na , typically with a higher potency of blocking late I Na vs. peak I Na [26] . Relatively low concentrations of I Na blockers (including TTX, lidocaine, quinidine, ranolazine, etc) can potently inhibit late I Na without affecting peak I Na [1, 26] . Selective pharmacological augmentation of late I Na prolongs APD/ERP and reduction of this current leads to an abbreviation of APD/ERP (Fig. 1) . Block of late I Na reduces Na i (and thus Ca i ) and does not directly affect cardiac excitability or conduction properties. Most data dealing with the pharmacology of late I Na were obtained using ventricular myocytes.
Pharmacology of Late I Na in Ventricles
The role played by late I Na is often investigated using ranolazine, currently the most potent late I Na blocker in ventricles [5] . Ranolazine has been shown to be 9 to 45 times more potent in blocking late vs. peak I Na in isolated ventricular myocytes and expression systems [5, [27] [28] [29] . The study by Udrovinas and colleagues [28] reported an exceptional selectivity of ranolazine to inhibit late vs. peak I Na in canine ventricular cells (6.5 vs. 294 μM, respectively; i.e., demonstrating an IC 50 ratio of 45). Contributing to this high selectivity was the fact that ranolazine's blocking potency was measured at a cycle length (CL) of 10 s, at which the use-dependent effects of the drug are not apparent [14, 30] . Indeed, in canine ventricular myocytes, at slow rates and negative holding potentials (at which all sodium channels are available), 285 μM of ranolazine was needed to cause a 50 % reduction (IC 50 ) of peak I Na , whereas at faster rates and more "physiological" holding potentials IC 50 was less than 10 % of that value [30] . Late I Na IC 50 values for ranolazine inhibition also depend on recording conditions and can range between from 5 to 21 μM in canine ventricular myocytes [24] . Thus, the IC 50 of I Na blockers to inhibit both late and peak I Na can vary significantly depending on the conditions at which IC 50 is measured, including stimulation rate, diastolic interval, holding and test potentials, and temperature [24, 29, 30] . The differences in functional manifestation of late vs. peak I Na inhibition in multicellular preparations can be even more pronounced, as discussed below.
I Na blocker-induced inhibition of both peak and late I Na is rate-dependent (i.e., the faster the rate the greater the blocking efficacy) [12, 24, 26, 29] . The rate-dependence of peak I Na block is particularly steep for I Na blockers with rapid unbinding kinetics, such as ranolazine, vernakalant, and amiodarone [14, 26, [30] [31] [32] . The rate-dependence of peak vs. late I Na inhibition is not well investigated. In HEK293 cells expressing a LQT3 mutation (SCN5A-R1623Q), ratedependent effect of ranolazine to block late and peak I Na is similar [29] . In cardiac cells, the functional manifestations of rate-dependent peak I Na block is generally greater than that of late I Na block (Fig. 4) . I Na blockers with rapid kinetics (e.g., ranolazine and lidocaine) can be highly selective late I Na blockers at slow heart rates and much less selective or non-selective for late I Na block at rapid activation rates. Indeed, ranolazine and lidocaine (10-20 μM) significantly abbreviate APD (due to late I Na block) but have little to no affect on V max in Purkinje fiber and ventricular M cell preparations at CLs ≥1000 ms [24, 33] , thus demonstrating high selectivity for block of late vs. peak I Na . ventricles under baseline conditions and the APD in atrium is significantly abbreviated in remodeled atria (in the setting of atrial fibrillation or prone to develop atrial fibrillation). APD abbreviation reduces the period during which late I Na flows into the cell, and thus the relative contribution of this current to intracellular sodium (Na i ) loading
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Late I Na Peak I Na Fig. 3 Acceleration of heart rate can lead to a reduction in late I Na total charge in the cardiac cell because of direct rate-dependent reduction in late I Na density as well as abbreviation of APD. The latter is in part due to the former. Acceleration of pacing rate reduces late I Na density more than that of peak I Na [9, [23] [24] [25] At rapid rates, these agents significantly reduce V max with little or no change in APD in ventricular muscles and Purkinje fibers, consistent with much less selective block of late I Na . Ranolazine (20 μM) causes a 30-40 % reduction of V max at a CL of 300 ms in canine and human ventricular slice preparations [34] . In canine and human ventricular preparations, ranolazine (10 μM) reduces V max by 8 and 20 % at a CL of 500 and 300 ms, respectively [14, 34] .
Pharmacology of Late I Na in Atria
There are fundamental differences in the response of atria and ventricles to block of peak I Na . I Na blockers with relatively rapid unbinding kinetics (like ranolazine amiodarone, vernakalant, AZD1305, Wenxin Keli, etc) are atrial-selective peak I Na blockers (Figs. 5 and 6 ). The rate-dependent potency of these agents to inhibit peak I Na and to depress peak I Na -mediated parameters (V max , conduction velocity, excitability, etc) in atrial cells is much greater than in ventricular cells (Figs. 5 and 6) [14, 30, 32, [34] [35] [36] [37] [38] . Ranolazine (10 μM), for example, produces little to no change in V max at a CL of ≥1000 ms in the canine right atrium, but reduces V max by 25 and 60 % at CLs of 500 and 300 ms, respectively [14, 39] . A major electrophysiological effect of ranolazine, amiodarone, vernakalant, etc (most relevant to their anti-AF action) is the induction atrial-selective post-repolarization refractoriness (PRR), a peak I Na -mediated parameter (Fig. 5) . Our current understanding of the mechanisms of atrial selectivity of I Na blockers have been discussed in detail elsewhere [39] [40] [41] and includes a more depolarized RMP, more negative halfinactivation voltage (V 0.5 ), and more gradual phase 3 of the action potential in atrial cells as compared with ventricular cells. It is not known whether atrial-selective peak I Na blockers cause atrial-selective inhibition of late I Na .
It is noteworthy that despite the rate-dependence of late I Na inhibition, the total charge of blocked late I Na may actually decrease with acceleration of pacing rate due to significant rate-dependent reduction of baseline late I Na density and abbreviation of APD (Figs. 3 and 4) . This suggests that the anti-arrhythmic action of late I Na block is likely reduced with acceleration of heart rate. Considering the shorter APD in atria vs. ventricles and atrial selectivity of peak I Na block, I Na blockers with rapid unbinding kinetics are likely to be less specific late I Na blockers in atria vs. ventricles, particularly at rapid activation rates.
Pathological conditions often modulate the potency of antiarrhythmic drugs. The efficacy of I Na blockers to inhibit late I Na in the setting of AF is poorly defined. The efficacy of ranolazine to inhibit late I Na is increased and that of peak I Na is reduced in atrial myocytes isolated from patients with persistent AF [17] . The physiological and anti-AF consequences of these altered blocking efficacies are not clear. However, it is known that I Na blockers, including ranolazine [42] , tend to lose their anti-AF effectiveness in persistent AF patients/models (as discussed in the next section). A reduced ability of ranolazine to block peak I Na in persistent AF patients is expected to decrease the effectiveness of the drug to induce PRR, thus limiting its anti-AF potency. Selective block of late I Na is expected to cause a greater APD abbreviation in "healthy" vs. remodeled atria (Fig. 7) .
Anti-Arrhythmic Efficacy of Late Sodium Current Inhibition
The anti-arrhythmic benefit of late I Na inhibition and the role of late I Na augmentation in arrhythmogenesis is considerably more studied in ventricles than in atria [5, 43, 44] . Fig. 4 Effect of acceleration of rate on total charge of atrial peak and late I Na in the absence and presence of sodium channel blockers with rapid unbinding kinetics. This schema applies only to I Na blockers that dissociate rapidly from the sodium channel, such as ranolazine, lidocaine, amiodarone (prominent late I Na blockers). Under baseline conditions, acceleration of pacing rates significantly reduces total charge of late I Na much more than that of peak I Na (due to decrease in late I Na density and APD abbreviation; see Fig. 3 ). At slow pacing rates and long APDs, block of late I Na is evidenced by a prominent abbreviation of APD and lack of block of peak I Na is evidenced by a lack of effect on V max . At rapid activation rates and relatively short APD, druginduced block of both late and peak I Na is augmented. Despite a ratedependent increase in potency of drug-induced late I Na block, there is a reduction in absolute amount of total charge of late I Na blocked following acceleration due to a significant reduction of available predrug total charge of late I Na integral secondary to a reduction of late I Na density and abbreviation of APD. Due to a much steeper ratedependent bock of peak I Na in atria vs. ventricles, the degree of ratedependent augmentation of peak vs. late I Na block is likely to be greater in atria vs. ventricles
Understanding the anti-arrhythmic utility of late I Na inhibition requires an understanding of the electrophysiological mechanisms underlying the generation of cardiac arrhythmias as well as some atrioventricular differences in arrhythmogeneicity. The occurrence of AF is commonly associated with abbreviation of APD and ERP. In contrast, ventricular tachycardia (VT) and fibrillation (VF) are relatively rarely associated with an abbreviated APD and ERP (i.e., short QT syndrome, acute ischemia, etc.). VT/VF more often occurs under conditions of prolonged APD (heart failure, hypotrophy, long QT syndrome, etc). Sustained electrical remodeling (due to prolonged rapid activation) is associated abbreviation of APD and ERP in atria but prolongation of APD in the ventricles [21, 45] . [14] , with permission. PRR is a peak I Na -mediated parameter Tachycardia and fibrillation are normally triggered by a focal source and maintained by a reentrant mechanism [46] . Focal mechanisms include early (EAD) and delayed (DAD) afterdepolarization-induced triggered activity and automaticity [47] . EAD is normally associated with a prolonged APD and bradycardia. An exception is the late phase 3 EAD which requires a significant abbreviation of APD. Phase 3 EAD-induced triggered activity usually develops following an episode of tachycardia followed by a pause [48] . The appearance of DAD is normally associated with tachycardia and relatively short APD. Ca i overload is a common source of induction of EAD-and DAD-induced triggered activity as well as accelerated automaticity. Reentrant mechanisms are often associated with conduction disturbances and structural and electrical heterogeneities [46] . Most arrhythmic mechanisms are commonly suppressed by APD/ERP prolongation; an exception is bradycardia-mediated EAD activity, which can be inhibited by APD abbreviation [46] .
The electrophysiological consequences of late I Na inhibition (described in the previous sections) suggest that the major anti-arrhythmic value of late I Na block is in suppression of Ca i -mediated triggered activity, particularly those occurring in conjunction with APD prolongation and bradycardia.
Ventricular Arrhythmias
Late I Na has attracted a great deal of attention as an antiarrhythmic target to suppress ventricular arrhythmias, particularly under conditions of prolonged repolarization, such as those associated with the long QT syndrome, heart failure and bradycardia. These anti-arrhythmic actions of inhibition of late I Na are due to reduction of repolarization heterogeneity secondary to preferential abbreviation of M cell action potential and suppression of EAD-and DAD-induced triggered activity [5, 24, 49] . EADs associated with a prolongation of repolarization can be suppressed by direct reduction of late I Na , leading to APD abbreviation (Fig. 8) . Abbreviation of APD with late I Na block may also reduce the total charge carried by the L-type Ca channel current as well, which may contribute to reduction of Ca i . Because of the presence of a high density of late I Na in M cells, late I Na can importantly abbreviate APD in these cells, thus reducing dispersion of repolarization, and suppressing EADs in all long QT types [5, 50] .
Ranolazine has been shown to suppress VF in the setting of myocardial ischemia in pigs in vivo [51, 52] . In addition to its late I Na inhibition, peak I Na block by ranolazine may have contributed to this anti-arrhythmic effect of ranolazine, since ERP was significantly prolonged [51] . Ischemia commonly produces depolarization of RMP, which strongly promotes peak I Na block. Ranolazine (10 μM) effectively suppresses H 2 0 2 -induced VF in rat [53] . Because H 2 0 2 promotes late I Na , ranolazine's inhibition of late I Na is likely to importantly contribute to VF suppression. In this study, V max and conduction velocity were significantly decreased by ranolazine [53] , indicating block of peak I Na .
Atrial Arrhythmias
The therapeutic benefits of peak I Na block in the setting of AF have long been recognized. The anti-AF action of peak I Na blockers is due largely to rate-dependent reduction of excitability, prolongation of ERP (secondary to the development of post-repolarization refractoriness), and to conduction block in a critical part of reentrant circuit. Reduction of peak I Na can also significantly decrease Na i and, thus, Ca i , which may suppress Ca i -mediated triggered activity. There is little information regarding the role of late I Na in the generation of AF and even less information on potential pharmacological outcomes of the inhibition of this current on AF. In a recent comprehensive review of ranolazine's anti-arrhythmic actions in ventricles and atria, it was concluded that anti-AF ability of ranolazine is largely due to inhibition of peak I Na and that anti-AF value of late I Na inhibition appears to be limited to the suppression of trigger(s) under conditions of prolonged atrial repolarization [5] .
Clinical and experimental experience indicates that practically all effective anti-AF agents prolong atrial ERP [41, 54] . Potassium channel blockers prolong ERP due to APD prolongation, whereas sodium channel blockers prolong "Healthy" atrium Remodeled atrium Control Late I Na block Fig. 7 Selective late I Na inhibition produces a greater APD abbreviation in healthy vs. remodeled atrial cells Late I Na block I Kr block Fig. 8 Late I Na block is effective in suppressing early afterdepolarizationinduced triggered activity. The principal mechanisms underlying suppression of early afterdepolarizations by selective late I Na inhibition include: 1) reduction of inward current and 2) decrease of Na i and thus Ca i ERP due to induction of rate-dependent post-repolarization refractoriness (PRR); mixed blockers prolong ERP due to both APD prolongation and PRR induction. Because selective late I Na block does not prolong ERP, reduction of late I Na alone is unlikely to be significantly effective for the suppression of AF. In fact, inhibition of late I Na acts to abbreviate APD (Fig. 7 and 8 ) which may promote AF.
AF is believed to be largely maintained by a reentrant mechanism. Reentrant AF can be suppressed by peak I Na blockers via reduction of excitability and prolongation of ERP and are unlikely to be significantly affected by selective late I Na inhibition.
Late I Na inhibition may however suppress the trigger(s) that initiate AF, particularly under conditions of prolonged APD and bradycardia. Several experimental and clinical studies point to the development of atrial arrhythmias under "atrial" long QT [55] [56] [57] . However, clinical experience indicate that repolarization prolonging agents induce proarrhythmias in ventricles but not in atria [58] [59] [60] , and that only a minority of congenital long QT patients develop AF (<2 %) [61] . Among these patients only one out of 59 LQT3 patients had AF [61] . In another study, 3.2 % of patients with early-onset AF have a SCN5A mutation or rare variant previously associated with long QT3 [62] . Consistent to these clinical data, experimental conditions mimicking LQT1, 2 and 3 and which produce EADs and Torsade de Pointes in canine ventricles [63, 64] , do not induce EAD or any arrhythmias in canine atria [65] . It appears that late I Na inhibition can prevent AF initiation in the "atrial long QT" patients, but the number of patients is likely to be limited.
Apart from long QT syndrome, there are a number of pathological conditions prone to AF which may be associated with a prolongation of atrial APD/ERP and AF occurrence, such as the congestive heart failure [66] , atrial dilatation [67, 68] and hypertension [18, 69] . It is noteworthy that in most of these studies [67] [68] [69] , ERP but not APD was measured and that in many pathological conditions (including heart failure) atrial ERP can prolong without APD prolongation (due to PRR development) [70] . Interestingly, aging, a major pro-AF factor, seems also to be associated with a prolongation of APD and ERP [71, 72] . It is tempting to speculate that prolonged atrial APD in these pathologies and aging is due at least in part to an increase in total charge of late I Na . Lengthening of APD in atrial myocytes (secondary to an increase in late I Na ) promotes Na i and then Ca i loading, leading to the generation of triggered activity and ranolazine has been shown to suppress these activities [73] . Atrial APD is likely to be short in patients experiencing AF or having frequent episodes of AF with any pathology, due to rapid activation-mediated electrical remodeling [21] . Atrial APD can be prolonged in patients who are prone to develop new-onset AF and patients experiencing rare/short episodes of AF, not causing sustained electrical remodeling in atria. In these cases, abbreviation of APD by block of late I Na may prevent AF initiation.
Tachycardia-mediated triggered activity appears to be less responsive to inhibition of late I Na compared to bradycardia-mediated triggered activity in atria (Figs. 3  and 4) . Ranolazine (10 μM) has been shown to prevent DAD-induced triggered activity (2.0-0.5 Hz) appearing following a period of rapid pacing (5-10 Hz) in superfused canine pulmonary vein (PV) preparations [74] . The primary mechanism of this action of ranolazine appears to be due largely to block of peak I Na , because ranolazine (10 μM) causes a significant V max reduction and development of PRR in these PVs [74] . Also, under conditions of a very short APD (APD 85 <100 ms) and rapid pacing rates (CL0 200-100 ms), ranolazine-induced reduction of Na i in PV muscular sleeves is likely to be largely due to block of peak I Na rather than late I Na . It needs to be recognized that the contribution of late vs. peak I Na block in the anti-arrhythmic action of ranolazine (or any other I Na blocker) is difficult to determine. In fact, block of peak I Na without inhibition of late I Na is not possible. It is likely that it is a combination of late and peak I Na inhibition that suppresses the appearance of the Ca i -mediated triggered activity.
Experimental evidence indicates that ranolazine effectively prevents, terminates, and/or shortens AF only at concentrations that potently inhibit peak I Na in atria (>5-10 μM), causing a significant rate-dependent depression of excitability and prolongation of PRR [14, 42, [75] [76] [77] . Relatively low concentrations of ranolazine (4-5 μM, which are more selective for block of late I Na but still capable of causing measurable inhibition peak I Na (Figs. 5 and 6) [14, 75] , are less effective against AF [42, 75] . An exception to this rule is AF occurring in the setting of ischemia/reperfusion in atria, where 5 μM ranolazine causes a strong rate-dependent ERP prolongation due to development of PRR and effectively prevents the induction of AF (Fig. 9) [14] . Ranolazine also inhibit late I Ca current (25-30 % at 2-6 μM [24] ) and cause weak block of β-adrenergic receptors [78] , which may contribute to its anti-arrhythmic effect. A combination of ranolazine and either dronedarone or amiodarone causes synergistic atrial-selective block of peak I Na , thus effectively suppressing and preventing the induction of AF in a canine experimental model of AF [75, 79] .
The clinical anti-AF efficacy of ranolazine has been demonstrated in several studies. In the MERLIN-TIMI 36 trial, ranolazine treatment was associated with a significant reduction of supraventricular tachyarrhythmias (p<0.001) as well as a 30 % reduction in new onset AF (p00.08) [80] . Subsequently, a number of small exploratory clinical studies showed the effectiveness of ranolazine to terminate paroxysmal AF [81, 82] and prevent post-operative AF [83] . Ranolazine has been shown also to facilitate electrical cardioversion of AF in cardioversion-resistant patients [84] as well as to improve effectiveness of amiodarone to terminate paroxysmal AF [85] .
Apart from ranolazine, there is an abundance of data on the effectiveness of I Na blockers against AF in both experimental and clinical studies [41, 54, 59] , from which the utility of late I Na inhibition can be deduced. Highly selective I Na blockers (lidocaine, mexiletine etc, at therapeutically relevant concentrations) are usually not effective against AF, suggesting that reduction of peak and late I Na (and thus Na i ) alone may be insufficient to effectively terminate and/or prevent AF. In experimental studies, lidocaine suppresses AF only at concentrations causing strong suppression of excitability due to peak I Na inhibition (clinically toxic concentrations) [14, 86] . Of note, all clinically effective I Na blockers (including ranolazine) inhibit other currents, particularly I Kr [40] . In fact, I Kr blockinduced prolongation of atrial repolarization (APD 90 ) greatly synergizes the effect of these agents to depress peak I Na , at rapid activation rates (Fig. 6) [14, 35, 87] .
The anti-AF efficacy of anti-arrhythmic drugs that block I Na (flecainide, propafenone, amiodarone, etc) is relatively high with paroxysmal AF but low or absent with persistent AF [59] . Available evidence indicates that ranolazine loses its anti-AF efficacy in experimental models of persistent lone AF in the goat [42] . In this respect, the anti-AF value of the increased efficacy of ranolazine to inhibit late I Na in persistent AF [17] is not clear. A reduced efficacy of ranolazine to block peak I Na in persistent AF [17] may account for or contribute to the failure of this agent (and perhaps the other I Na blockers) to terminate persistent AF.
The anti-AF efficacy of ranolazine in specific pathological conditions associated with AF remains poorly studied. It has been reported that ranolazine (5 μM) is effective in preventing AF in canine ischemia/reperfusioninduced AF model [14] as well as AF in canine ventricular tachypacing-induced heart failure model [70] . In both studies, anti-AF efficacy of ranolazine has been largely attributed to block of peak I Na .
Conclusion
At present there is little specific information regarding the role of late I Na in the generation of AF and even less information on potential pharmacological outcomes of the Fig. 9 Ranolazine suppresses AF and/or prevents its induction in two experimental models involving isolated canine arterially-perfused right atria. a Persistent ACh (0.5 μM)-mediated AF is suppressed by ranolazine (10 μM). AF initially converts to flutter and then to sinus rhythm. b ERP measured at a CL of 500 ms is 140 ms. Attempts to re-induce AF fail because ranolazine-induced depression of excitability leads to 1:1 activation failure soon after CL is reduced from 500 to 200 ms (right panel). c Rapid-pacing induces non-sustained AF (48 s duration) following ischemia/reperfusion plus isoproterenol (Iso, 0.2 μmol/L) (left panel). Ranolazine (5 μM) prevents pacing-induced AF due to 1:1 activation failure (right panel). In both models, ranolazine causes prominent use-dependent induction of post-repolarization refractoriness. Reproduced with permission from Burashnikov et al. [14] specific inhibition of this current on AF. Agents that potently block late I Na in the ventricles, such as ranolazine and amiodarone, are also atrial-selective peak I Na blockers and their anti-AF efficacy is due largely to inhibition of peak I Na . The anti-arrhythmic effectiveness of selective late I Na inhibition is thought to be greater when APD is long and heart rate is slow. The anti-arrhythmic efficacy of late I Na block is reduced following acceleration of heart rates and/or abbreviation of APD. Available data suggest that block of late I Na contributes to prevention of Ca i -mediated triggered activity capable of initiating AF, particularly in clinical pathologies associated with a prolonged atrial APD (such as long QT syndrome)
